Diary: Difference between revisions
Kenta Koyama (talk | contribs) No edit summary |
Kenta Koyama (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
=== April === | === April === | ||
[[17th]] | |||
'''the first meeting''' | |||
'' Team Todai nanORFEVRE'' was fixed as the name of our team. | |||
Yearly schedule was checked. | |||
We read in turn following two reviews of the structural DNA nanotechnology. | |||
*Andre V. Pinheiro1, Dongran Han1,2, William M. Shih3,4,5* and Hao Yan1,2* ''Challenges and opportunities for structural DNA nanotechnology'' | |||
*Nadrian C. Seeman'' Nanomaterials Based on DNA'' Department of Chemistry, New York University, New York, New York 10003 | |||
[[24th]] | |||
'''the second meeting''' | |||
=== May === | === May === | ||
[[1st]] | [[1st]] | ||
'''the third meeting''' | |||
We read in turn following two papers. | |||
*Qiao Jiang,†Chen Song,†Jeanette Nangreave,‡Xiaowei Liu,‡Lin Lin,§Dengli Qiu,#Zhen-Gang Wang,†Guozhang Zou,†Xingjie Liang,†Hao Yan,*,‡and Baoquan Ding ''DNA Origami as a Carrier for Circumvention of Drug Resistance'' | |||
The summary is as follows: | |||
DNA origami as carrierThe DNA origami nanostructure, which is biocompatible and have spatially addressable surfaces for multi-functional activity, is presented as a promising drug carrier system in the treatment of cancer. It effectively loaded Doxorubicin, a well known anticancer drug, with itself and exhibited prominent citotoxity not only to regular human breast adenocarcinoma cancer cells (MCF 7), but more importantly to doxorubicin-resistant cancer cells. It seems that the inhibition of the lysosomal acidification, resulting in cellular redistribution of the drug to action sites contributes to that. | |||
[[8th]] | [[8th]] | ||
[[15th]] | [[15th]] | ||
[[22th]] | [[22th]] | ||
[[29th]] | [[29th]] | ||
Revision as of 14:10, 11 June 2013
April
the first meeting
Team Todai nanORFEVRE was fixed as the name of our team. Yearly schedule was checked.
We read in turn following two reviews of the structural DNA nanotechnology.
- Andre V. Pinheiro1, Dongran Han1,2, William M. Shih3,4,5* and Hao Yan1,2* Challenges and opportunities for structural DNA nanotechnology
- Nadrian C. Seeman Nanomaterials Based on DNA Department of Chemistry, New York University, New York, New York 10003
the second meeting
May
the third meeting
We read in turn following two papers.
- Qiao Jiang,†Chen Song,†Jeanette Nangreave,‡Xiaowei Liu,‡Lin Lin,§Dengli Qiu,#Zhen-Gang Wang,†Guozhang Zou,†Xingjie Liang,†Hao Yan,*,‡and Baoquan Ding DNA Origami as a Carrier for Circumvention of Drug Resistance
The summary is as follows: DNA origami as carrierThe DNA origami nanostructure, which is biocompatible and have spatially addressable surfaces for multi-functional activity, is presented as a promising drug carrier system in the treatment of cancer. It effectively loaded Doxorubicin, a well known anticancer drug, with itself and exhibited prominent citotoxity not only to regular human breast adenocarcinoma cancer cells (MCF 7), but more importantly to doxorubicin-resistant cancer cells. It seems that the inhibition of the lysosomal acidification, resulting in cellular redistribution of the drug to action sites contributes to that.
